Nothing Special   »   [go: up one dir, main page]

MX2019014934A - Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas. - Google Patents

Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.

Info

Publication number
MX2019014934A
MX2019014934A MX2019014934A MX2019014934A MX2019014934A MX 2019014934 A MX2019014934 A MX 2019014934A MX 2019014934 A MX2019014934 A MX 2019014934A MX 2019014934 A MX2019014934 A MX 2019014934A MX 2019014934 A MX2019014934 A MX 2019014934A
Authority
MX
Mexico
Prior art keywords
methods
combination therapy
brain tumors
treating brain
treating
Prior art date
Application number
MX2019014934A
Other languages
English (en)
Inventor
David Schenkein
Nelamangala Nagaraja
Joshua Murtie
Brandon Nicolay
Katharine Yen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2019014934A publication Critical patent/MX2019014934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan métodos para tratar un tumor cerebral en un paciente que lo necesita que comprende administrar al paciente un compuesto descrito en la presente descripción y una terapia de radiación y/o uno o más agentes terapéuticos adicionales.
MX2019014934A 2017-06-12 2018-06-12 Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas. MX2019014934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518565P 2017-06-12 2017-06-12
PCT/US2018/037062 WO2018231796A1 (en) 2017-06-12 2018-06-12 Methods of treating brain tumors using combination therapy

Publications (1)

Publication Number Publication Date
MX2019014934A true MX2019014934A (es) 2022-06-28

Family

ID=62815154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014934A MX2019014934A (es) 2017-06-12 2018-06-12 Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.

Country Status (12)

Country Link
US (4) US10780093B2 (es)
EP (1) EP3638245A1 (es)
JP (3) JP7263669B2 (es)
KR (1) KR102725746B1 (es)
CN (2) CN119280245A (es)
AU (1) AU2018284101B2 (es)
BR (1) BR112019026378A2 (es)
CA (1) CA3067028A1 (es)
IL (1) IL271307A (es)
MX (1) MX2019014934A (es)
TW (2) TWI830700B (es)
WO (1) WO2018231796A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018284101B2 (en) * 2017-06-12 2024-06-06 Les Laboratoires Servier Methods of treating brain tumors using combination therapy
EP4041922A4 (en) 2019-10-07 2023-11-01 University Hospitals Cleveland Medical Center METHOD FOR TREATING WILD-TYPE ISOCITRATE DEHYDROGENASE-1 CANCER

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2184545A1 (en) 1996-07-31 1998-02-01 Pascale Reidenberg Cancer treatment with temozolomide
ES2740424T3 (es) * 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
CA2793836C (en) * 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
JP2014523421A (ja) * 2011-06-17 2014-09-11 ハリス，エイドリアン，エル． 抗ｄｌｌ４抗体を使用して腫瘍治療における放射線に対する反応を増大させる方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX360189B (es) 2012-08-07 2018-10-24 Genentech Inc Terapia de combinacion para el tratamiento de glioblastoma.
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) * 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR20180023968A (ko) * 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법
MD3362065T2 (ro) 2015-10-15 2024-08-31 Servier Lab Terapie combinată care conține ivosidenib, citarabină și daunorubicina sau idarubicina pentru tratarea leucemiei acute mielogene
EP3362070B1 (en) * 2015-10-15 2021-01-27 Celgene Corporation Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia
AU2018284101B2 (en) * 2017-06-12 2024-06-06 Les Laboratoires Servier Methods of treating brain tumors using combination therapy

Also Published As

Publication number Publication date
BR112019026378A2 (pt) 2020-07-21
US20240325401A1 (en) 2024-10-03
IL271307A (en) 2020-01-30
TWI830700B (zh) 2024-02-01
EP3638245A1 (en) 2020-04-22
AU2018284101B2 (en) 2024-06-06
CN111182905A (zh) 2020-05-19
WO2018231796A1 (en) 2018-12-20
JP2023025277A (ja) 2023-02-21
CA3067028A1 (en) 2018-12-20
US10780093B2 (en) 2020-09-22
AU2018284101A1 (en) 2019-12-19
JP2023025276A (ja) 2023-02-21
TW202440123A (zh) 2024-10-16
US12042497B2 (en) 2024-07-23
US20180353514A1 (en) 2018-12-13
JP7529755B2 (ja) 2024-08-06
TW201902484A (zh) 2019-01-16
KR20200015745A (ko) 2020-02-12
JP7263669B2 (ja) 2023-04-25
US12064436B2 (en) 2024-08-20
JP2020523412A (ja) 2020-08-06
US20220362250A1 (en) 2022-11-17
US20210046081A1 (en) 2021-02-18
CN119280245A (zh) 2025-01-10
KR102725746B1 (ko) 2024-11-01

Similar Documents

Publication Publication Date Title
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
BR112019021822A2 (pt) Terapia de combinação
IL280707A (en) Diagnostic and therapeutic methods for treating breast cancer
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
WO2016025635A3 (en) Combination therapy for treating cancer
CR20170477A (es) Terapia de combinacin del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cncer
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
NI201500151A (es) Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
MX2020001727A (es) Terapia de combinacion.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
BR112018002530A2 (pt) combinações e usos e tratamentos destas
CO2022007361A2 (es) Terapia de combinación para el tratamiento de cáncer cerebral
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.